The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution
Open accessAbstract
The blood glucose‐lowering efficacy of rosiglitazone (RSG) and the mechanisms of associated weight gain were determined in dietary obese rats (DIOs). DIO and chow‐fed rats received RSG 0.3–30 mg kg−1 daily for 21 days. In DIOs, plasma glucose and insulin concentrations were reduced by RSG at dosages of 3 and 10 mg kg−1, respectively. Homeostasis model assessment (HOMA) indicated the threshold for a reduction of insulin resistance was 1 mg kg−1. Neither glucose nor insulin levels were affected by treatment in chow‐fed rats. RSG 0.3 mg kg−1 lowered free fatty acids (FFAs) in DIOs, whereas for plasma triglycerides (TGs), the threshold was 3 mg kg−1. By contrast, the threshold for reducing packed red cell volume (PCV) and increasing cardiac mass was 10 mg kg−1. Thus, the therapeutic index for RSG in DIOs was >3 and 10. Energy intake and weight gain increased in treated DIOs (by 20% and 50 g, at 30 mg kg−1) and chow‐fed rats (by 25% and 35 g, at 30 mg kg−1). In DIOs, these increases coincided with falls in plasma leptin (40% lower at 30 mg kg−1) and insulin (43% lower at 30 mg kg−1). By contrast, in chow‐fed rats, weight gain and hyperphagia occurred without changes in either leptin or insulin. However, reductions in FFAs below 0.4–0.3 m M were associated with hyperphagia and weight gain in DIO and chow‐fed rats. We conclude that increased energy intake and body weight did not attenuate the improved metabolism evoked by RSG in DIO rats, and that insulin action was enhanced at a dose >3 fold below the threshold for causing haemodilution and cardiac hypertrophy in DIO rats. British Journal of Pharmacology (1999) 128, 1570–1576; doi:10.1038/sj.bjp.0702932
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Randle, P. J., Garland, P. B., Hales, C. N., & Newsholme, E. A. (1963) · The Lancet · doi:10.1016/s0140-6736(63)91500-9 · Cited by 5,093 · cited 1×
“In essence, our data in DIO rats support the hypothesis that the insulin-sensitizing e ect of RSG is closely linked to the reduced availability of fatty acids as a fuel for skeletal muscle (Oakes et al., 1994, 1997) via the Randle cycle (Randle et al., 1963).”
BackgroundMartin, G., Schoonjans, K., Lefebvre, A.-M., Staels, B., & Auwerx, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.45.28210 · Cited by 551 · cited 2×
“…ã 1999 Stockton Press All rights reserved 0007 ± 1188/99 $15.00 http://www.stockton-press.co.uk/bjp 1996; Ibrahimi et al., 1994; Lefebvre et al., 1997; Martin et al., 1997; Paulik et al., 1997; Pearson et al., 1996; Tai et al., 1996) and changes to energy intake (Shimizu et al., 1998; Wang et…”
BackgroundInfluentialBerger, J., Bailey, P., Biswas, C., Cullinan, C. A., Doebber, T. W., Hayes, N. S., Saperstein, R., Smith, R. G., & Leibowitz, M. D. (1996) · Endocrinology · doi:10.1210/endo.137.10.8828476 · Cited by 391
Cited by
Use and Abuse of HOMA Modeling
Wallace, T. M., Levy, J. C., & Matthews, D. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1487 · Cited by 5,114
Larsen, T. M., Toubro, S., & Astrup, A. (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.802223 · Cited by 282
Metadata
- Authors
- Pickavance, L. C., Tadayyon, M., Widdowson, P. S., Buckingham, R. E., & Wilding, J. P. H.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 1999-12
- Volume
- 128
- Issue
- 7
- Pages
- 1570-1576
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2055943486
- Cited by
- 160
- References
- 4
- FWCI
- 1.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.